159 related articles for article (PubMed ID: 30355512)
1. Administration of teriparatide for four years cyclically compared to two years daily in treatment Naïve and alendronate treated women.
Cosman F; Nieves JW; Roimisher C; Neubort S; McMahon DJ; Dempster DW; Lindsay R
Bone; 2019 Mar; 120():246-253. PubMed ID: 30355512
[TBL] [Abstract][Full Text] [Related]
2. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
[TBL] [Abstract][Full Text] [Related]
3. Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate.
Dempster DW; Cosman F; Zhou H; Nieves JW; Bostrom M; Lindsay R
J Bone Miner Res; 2016 Aug; 31(8):1518-26. PubMed ID: 26916877
[TBL] [Abstract][Full Text] [Related]
4. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
[TBL] [Abstract][Full Text] [Related]
5. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Lung S; Resch H
J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
[TBL] [Abstract][Full Text] [Related]
6. Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Ganapathy A; Nieves JW; Keaveny TM; Cosman F
Bone; 2023 Feb; 167():116618. PubMed ID: 36410666
[TBL] [Abstract][Full Text] [Related]
7. Mapping Bone Changes at the Proximal Femoral Cortex of Postmenopausal Women in Response to Alendronate and Teriparatide Alone, Combined or Sequentially.
Whitmarsh T; Treece GM; Gee AH; Poole KE
J Bone Miner Res; 2015 Jul; 30(7):1309-18. PubMed ID: 25639838
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
9. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
10. Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.
Hofstetter B; Gamsjaeger S; Varga F; Dobnig H; Stepan JJ; Petto H; Pavo I; Klaushofer K; Paschalis EP
Osteoporos Int; 2014 Dec; 25(12):2709-19. PubMed ID: 25037600
[TBL] [Abstract][Full Text] [Related]
11. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.
Finkelstein JS; Wyland JJ; Lee H; Neer RM
J Clin Endocrinol Metab; 2010 Apr; 95(4):1838-45. PubMed ID: 20164296
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
Ebina K; Hirao M; Hashimoto J; Hagihara K; Kashii M; Kitaguchi K; Matsuoka H; Iwahashi T; Chijimatsu R; Yoshikawa H
J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
[TBL] [Abstract][Full Text] [Related]
13. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
Stepan JJ; Burr DB; Li J; Ma YL; Petto H; Sipos A; Dobnig H; Fahrleitner-Pammer A; Michalská D; Pavo I
Osteoporos Int; 2010 Dec; 21(12):2027-36. PubMed ID: 20135094
[TBL] [Abstract][Full Text] [Related]
14. Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate.
Yano T; Yamada M; Inoue D
Calcif Tissue Int; 2017 Jul; 101(1):102-110. PubMed ID: 28337514
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture.
Hiligsmann M; Williams SA; Fitzpatrick LA; Silverman SS; Weiss R; Reginster JY
Semin Arthritis Rheum; 2019 Oct; 49(2):184-196. PubMed ID: 30737062
[TBL] [Abstract][Full Text] [Related]
16. Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.
Wermers RA; Recknor CP; Cosman F; Xie L; Glass EV; Krege JH
Osteoporos Int; 2008 Jul; 19(7):1055-65. PubMed ID: 18283386
[TBL] [Abstract][Full Text] [Related]
17. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
Cosman F; Wermers RA; Recknor C; Mauck KF; Xie L; Glass EV; Krege JH
J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
[TBL] [Abstract][Full Text] [Related]
18. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.
Le QA; Hay JW; Becker R; Wang Y
Ann Pharmacother; 2019 Feb; 53(2):134-143. PubMed ID: 30160186
[TBL] [Abstract][Full Text] [Related]
20. Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
Hagino H; Tanaka S; Kuroda T; Mori S; Soen S
J Bone Miner Metab; 2024 May; 42(3):382-388. PubMed ID: 38755328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
